11/15/2025
In 2026, Medicare coverage of GLP-1 drugs will expand to cover obesity, in addition to diabetes and some heart issues. In the US, 65% of the people 65 and older are considered obese, with a body mass index of 30.0 or higher.
Trump's deal slashes GLP-1 drug costs for Medicare beneficiaries and others, unlocking coverage for millions with obesity and related conditions.